2025
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database
Caturegli G, Zhu X, Palis B, Mullett T, Resio B, Boffa D. Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncology 2025, 11: 564-566. PMID: 40146125, PMCID: PMC11950973, DOI: 10.1001/jamaoncol.2025.0247.Peer-Reviewed Original ResearchPredicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsPrecision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias O, Mandell J, Anderson K, Townsend J. Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 2025, 202: 108487. PMID: 40090261, DOI: 10.1016/j.lungcan.2025.108487.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsCell lung cancerLung cancer patientsEvolution of drug resistanceLung cancerDrug resistanceCancer patientsTyrosine kinase inhibitor therapyKinase inhibitor therapyTyrosine kinase inhibitorsPersonalized therapeutic strategiesTKI therapyInhibitor therapyTherapeutic failureResistance mutationsTherapeutic efficacyKinase inhibitorsAPOBEC mutationsTherapeutic strategiesTreatment efficacyCancer progressionImprove outcomesCancerDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumorEfficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, Italiano A, Rieke D, Liu T, Burcoveanu D, Neu N, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal Of Cancer 2025, 220: 115338. PMID: 40068370, DOI: 10.1016/j.ejca.2025.115338.Peer-Reviewed Original ResearchTreatment-related adverse eventsSafety of larotrectinibMicrosatellite instability-highGI cancersMedian duration of responseNext-generation sequencing testMedian overall survivalProgression-free survivalDuration of responseNTRK gene fusionsOverall response rateFirst-in-classOverall survivalMedian durationTRK inhibitorsSolid tumorsTumor typesAdverse eventsExtended survivalLarotrectinibGastrointestinal cancerPatientsHepatic cancerResponse rateCancerTop advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approachSensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs
Dong C, Zhang F, He E, Ren P, Verma N, Zhu X, Feng D, Cai J, Zhao H, Chen S. Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs. Patterns 2025, 6: 101184. DOI: 10.1016/j.patter.2025.101184.Peer-Reviewed Original ResearchParalogous gene pairsParalogous pairsChimeric antigen receptor T cellsResponse to cancer immunotherapyDouble knockoutCancer immunotherapy responseGene pairsCheckpoint blockadeGenome-wide screenImmunotherapy efficacyCancer immunotherapyEnhance immunotherapyImmunotherapy responseImmunotherapy effectT cellsImmunotherapyCancer treatmentIndividual genesCRISPR screensEnrichment analysisParalogsCancerTreatmentCombined targetFunctional significanceBisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma
Yang Z, Chen Q, Dong S, Xu P, Mao Z, Dong Y, Li W, Li W, Han Y, Dai L, Dong G, Zhang Y, Li Y, Cheng L, Ci W, Yu W, Xu C. Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma. Bioengineering & Translational Medicine 2025 DOI: 10.1002/btm2.70004.Peer-Reviewed Original ResearchDetection of urothelial carcinomaStandard urine cytologyDetecting bladder cancerClinical detectionRenal pelvis cancerEarly noninvasive detectionUC tumorsUrine cytologyUrothelial carcinomaMale malignancyPelvis cancerEasy-to-performUreter cancerBladder cancerValidation setPatient enrollmentUrinary systemPatientsUrine samplesNoninvasive detectionUrineCancerEarly detectionCarcinomaMalignancyA pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
Mukhtar R, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy A, Laé M, Reyal F, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey J, Goetz M, Hoskin T, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Provenzano E, Sammut S, Thomas J, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, J van ’t Veer L, Cameron D, Esserman L, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. Npj Breast Cancer 2025, 11: 14. PMID: 39948079, PMCID: PMC11825822, DOI: 10.1038/s41523-025-00720-3.Peer-Reviewed Original ResearchResidual cancer burdenInvasive lobular carcinomaEvent-free survivalNeoadjuvant chemotherapyBreast cancerAssociated with worse event-free survivalResidual cancer burden indexInvasive lobular breast cancerCancer burdenLobular breast cancerNodal statusLobular carcinomaNAC responseT categoryPrognostic significanceStratify prognosisPatient-level dataReceptor subtypesPooled analysisMultivariate analysisPooled cohortRecursive partitioningCox modelCancer cellularityCancerModern-Day Hypofractionated Postmastectomy Radiation
Rybkin A, Bodofsky S, Knowlton C. Modern-Day Hypofractionated Postmastectomy Radiation. Current Breast Cancer Reports 2025, 17: 7. DOI: 10.1007/s12609-025-00570-9.Peer-Reviewed Original ResearchPostmastectomy radiationBreast cancerPost-mastectomy settingRegional nodal irradiationRadiobiological dataQuality of life metricsNodal irradiationBreast conservationEradicate tumorsComplication rateBrachial plexopathyPostmastectomy patientsToxicity profileHypofractionationFractionation schemaTherapeutic windowReviewThis reviewTissue effectsTrial dataBreastPostmastectomyStandard optionDisease controlPatientsCancerLow-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible?
Fuss C. Low-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible? Radiology 2025, 314: e250215. PMID: 39964272, DOI: 10.1148/radiol.250215.Peer-Reviewed Original ResearchMitochondrial succinate feeds T cell exhaustion in cancer
Galluzzi L, Guilbaud E, Garg A. Mitochondrial succinate feeds T cell exhaustion in cancer. Cancer Cell 2025, 43: 168-170. PMID: 39933894, DOI: 10.1016/j.ccell.2025.01.005.Peer-Reviewed Original ResearchEnteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis
Chow R, Im J, Arends J, Del Fabbro E, Mortensen-Truscott L, Qeska D, Balaji S, Walsh C, Watson G, Lock M, Prsic E, Eng L, Zimmermann C, Bruera E. Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis. BMJ Supportive & Palliative Care 2025, spcare-2024-005244. PMID: 39890439, DOI: 10.1136/spcare-2024-005244.Peer-Reviewed Original ResearchCumulative meta-analysisNutrition support complicationsSystematic reviewProtein-energy malnutritionEnteral nutritionParenteral nutritionMeta-analysisRandomised controlled trialsSubgroup analysisLeave-one-out analysisStandard careEffect estimatesControlled trialsType I errorComplication rateComplicationsAdultsNutritionPatientsInfectionInfection rateCancerMortalityEndpointChildrenDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosisAssociation between psychological flexibility and self-perceived burden in patients with cervical cancer: A computer-simulated network analysis
Chen F, Xiong Y, Li S, Deng Y, Zhang Q, Xiao Z, Knobf M, Ye Z. Association between psychological flexibility and self-perceived burden in patients with cervical cancer: A computer-simulated network analysis. European Journal Of Oncology Nursing 2025, 74: 102822. PMID: 39893708, DOI: 10.1016/j.ejon.2025.102822.Peer-Reviewed Original ResearchUnraveling complexity and leveraging opportunities in uncommon breast cancer subtypes
Pareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F, Desmedt C, Harigopal M, Lakhani S, Lee A, Leone J, Linden H, Lord C, Marchio C, Merajver S, Rakha E, Reis-Filho J, Richardson A, Sawyer E, Schedin P, Schwartz C, Tutt A, Ueno N, Vincent-Salomon A, Weigelt B, Wen Y, Schnitt S, Oesterreich S. Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes. Npj Breast Cancer 2025, 11: 6. PMID: 39856067, PMCID: PMC11760369, DOI: 10.1038/s41523-025-00719-w.Peer-Reviewed Original ResearchBreast cancerHistological subtype of breast cancerSubtypes of breast cancerBreast cancer subtypesHistological subtypesImmune microenvironmentBC presentationGenetic alterationsCancer subtypesGenetic predispositionMolecular profilingTherapeutic implicationsClinical trajectoryUnique phenotypeSubtypesBreastCancerMicroenvironmentPredispositionCorrection: Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal
Paneru B, Karmacharya A, Bharati A, Makaju S, Adhikari B, Kafle D, Shakya S, Donna S, Seth S, Stangl A, Shrestha A, Shrestha A. Correction: Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal. PLOS ONE 2025, 20: e0318367. PMID: 39854385, PMCID: PMC11759993, DOI: 10.1371/journal.pone.0318367.Peer-Reviewed Original ResearchA Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.Peer-Reviewed Original ResearchCholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer
Belabed M, Park M, Blouin C, Balan S, Moon C, Freed G, Quijada-Álamo M, Peros A, Mattiuz R, Reid A, Yatim N, Boumelha J, Azimi C, LaMarche N, Troncoso L, Amabile A, Le Berichel J, Chen S, Wilk C, Brown B, Radford K, Ghosh S, Rothlin C, Yvan-Charvet L, Marron T, Puleston D, Wagenblast E, Bhardwaj N, Lamaze C, Merad M. Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer. Nature Immunology 2025, 26: 188-199. PMID: 39838105, DOI: 10.1038/s41590-024-02065-8.Peer-Reviewed Original ResearchConventional dendritic cellsNiemann-Pick disease type C1Maturation of conventional dendritic cellsExpression of maturation markersCholesterol mobilizationAnti-tumor immunityReceptor tyrosine kinase AXLDendritic cell maturationResponse to cancerTyrosine kinase AXLDendritic cellsImmune receptor signalingMaturation markersAuto-immunityCell maturationReceptor signalingImmunogenic responseTherapeutic targetCholesterol transportLipid nanodomainsSubcellular mechanismsCholesterolType C1CancerCell surfaceHarnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, Tan D, Tan W, Ang H, Carbone D, Yee M, Shanmugam M, Huang X, Sethi G, Tan T, Lim L, Huang R, Ungefroren H, Giovannetti E, Tang D, Bruno T, Luo P, Andersen M, Qian B, Ishihara J, Radisky D, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper K, Shi T, Merghoub T, Krebs S, Kusumbe A, Davids M, Brown J, Kumar A. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. Journal Of Hematology & Oncology 2025, 18: 6. PMID: 39806516, PMCID: PMC11733683, DOI: 10.1186/s13045-024-01634-6.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTumor microenvironmentCancer progressionTherapeutic resistanceCancer therapyTumor microenvironment componentsTumor microenvironment modulationModulation of epithelial-mesenchymal transitionPromote tumor growthImprove treatment efficacyTumor microenvironment signalsTargeted cancer therapyTarget various componentsTherapeutic challengeTreatment responseTumor growthPromote metastasisTherapeutic strategiesTreatment efficacyEpithelial cellsMesenchymal traitsCancer cellsExtracellular matrix componentsCancerResistance mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply